CLEAR Outcomes
A Randomized, Double-blind, Placebo-controlled Study to Assess the Effects of Bempedoic Acid (ETC-1002) on the Occurrence of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant.
The purpose of this study is to determine if treatment with bempedoic acid (ETC-1002) versus placebo decreases the risk of cardiovascular events in patients who are statin intolerant.
Learn More
Please complete the form below if you are interested in joining a clinical study. Please note that not all who apply are accepted into a trial.
Menu
Newsletter
Sign up with your name and email address to obtain ongoing updates. Please know that you can ‘opt out’ at any time.
Please enter your name.
Please enter a valid email address.
Thanks for subscribing! Please check your email for further instructions to confirm your subscription.
Something went wrong. Please check your entries and try again.
Get In Touch
We’d love to hear from you!
Excel Medical Clinical Trials LLC
7900 Glades Road, Suite 400
Boca Raton, FL 33434
7900 Glades Road, Suite 400
Boca Raton, FL 33434